Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.88 +0.12 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
Friday: Quick Update
Britain - which I actually will be escaping soon - had a better market day than many foreign markets. 
Via Talk Markets
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients
ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, presented three-year results ... 
Via Benzinga
ViiV In-Licenses Third-Gen HIV Targeting Compound From Shionogi
ViiV Healthcare, majority-owned by GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, has announced an exclusive collaboration... 
Via Benzinga
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi... 
Via Benzinga
Exposures COVID-19
4 No-Brainer Pharmaceutical Stocks to Buy in October
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical... 
Via Talk Markets
Exposures COVID-19
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19... 
Via Benzinga
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Mond... 
Via Benzinga
Exposures COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
China's Rescue Of Evergrand
The number of jobless last week was higher than the forecast, at 351,000 vs 320,000. The recovery is lagging. 
Via Talk Markets
Green Hygienics Holdings To Raise $100M Via Green Bond Offering
Hemp company Green Hygienics Holdings Inc. (OTCQB:GRYN) is ... 
Via Benzinga
Why Are Theravance Bio Shares Plummeting Premarket Today?
Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November... 
Via Benzinga
4 Top Healthcare Stocks to Buy in September
In addition to playing a major role in helping the world fight the COVID-19 pandemic, the healthcare industry is making solid progress in addressing the rising health issues faced by an aging global... 
Via Talk Markets
Exposures COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. 
Via Talk Markets
Exposures COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would... 
Via Benzinga
Exposures COVID-19
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
Exposures COVID-19
Pete Najarian Sees Unusual Options Activity In Capri Holdings And GlaxoSmithKline
On CNBC's "Fast Money Halftime Report," Pete Najarian said he saw a buyer of 5,000 contracts of the November $57.50 calls in Capri Holdings Ltd (NYSE: CPRI) in the... 
Via Benzinga
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
This Med Tech Innovator Just Doubled, And It Can Do It Again
We’re here to crush the market with the foremost innovative tech leaders. 
Via Talk Markets
White House Commits $3B To Boost COVID-19 Vaccine Supply Chain: Report
The U.S. will invest $3 billion in the COVID-19 vaccine supply chain within the coming weeks, White House coronavirus response coordinator Jeff Zients said Thursday.... 
Via Benzinga
Exposures COVID-19
Can Vaccine Help In Long Term COVID-19 Symptoms? UK Study Gives Encouraging Answer
According to findings from a new U.K. study, along with reducing the risk of severe disease and hospitalization, COVID-19 vaccines can also lower the odds of having long-term... 
Via Benzinga
Exposures COVID-19
The Rising Delta Variant
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande. 
Via Talk Markets
Topics Bankruptcy
Exposures Financial Legal
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
3 Things About Pfizer That Smart Investors Know
They're all about the future. 
Via The Motley Fool
This Biotech Company Could Offer Nearly Unlimited Optionality
Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
EU Says Without EMA Approval COVID-19 Boosters May Face Higher Legal Risks: Reuters
European Union countries that decide to use COVID-19 vaccine booster shots may face increased legal risks, the European Commission said. Related Content: Pfizer, BioNTech... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.